Given the pivotal role of Mi-2β in regulating the immune response, targeting Mi-2β would represent a potential therapeutic strategy in melanoma immunotherapy, especially in combination with anti-PD-1 antibody therapies. This evidence concerns the gene CHD4 and melanoma.